Dihexa vs PE 22-28
A side-by-side research comparison of Dihexa and PE 22-28 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Dihexa | PE 22-28 |
|---|---|---|
| Full name | Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) | PE 22-28 (Spadin-Derived TREK-1 Peptide) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Research compound | Research peptide (preclinical) |
| Mechanism | Allosteric potentiator of HGF/c-Met signaling driving synaptogenesis, dendritic spine formation, and neuronal survival in hippocampal circuits. | Selectively blocks the TREK-1 background potassium channel. TREK-1 inhibition enhances serotonergic signaling and rapidly increases synaptogenesis and neurogenesis, producing antidepressant-like effects faster than SSRIs in animal models. |
| Molecular weight | 507.6 Da | ~ (7-residue peptide) |
| Half-life | 6-12 hours | Short (peptide; improved vs spadin) |
| Bioavailability | Moderate (oral/SubQ) | Intranasal or injection (research) |
| Typical dose | 10-20 mg (oral) or 2-5 mg (SubQ) | Not established for humans |
| Frequency | Daily | Research only |
| Route | Oral or Subcutaneous | Intranasal or injection (research) |
Dihexa reported benefits
- Dramatic synaptogenesis
- Memory improvement
- Cognitive restoration potential
- Dendritic spine growth
- HGF/c-Met activation
PE 22-28 reported benefits
- Rapid antidepressant effects (preclinical)
- Promotes neurogenesis and synaptogenesis
- TREK-1 channel blockade
- Neuroplasticity research interest
Related comparisons
Research and educational reference only. Not medical advice.